Advances in immunotherapy for MMR proficient colorectal cancer.
MetadataShow full item record
Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect profile in various cancer types and multiple clinical trials have been conducted in MMRp mCRC. In this review we summarise emerging trial data which demonstrate promising immunotherapy combinations in MMRp mCRC. We outline barriers to success, evaluate emerging biomarkers and discuss potential strategies to increase the effectiveness of immunotherapy in MMRp mCRC.
DNA Mismatch Repair
License start date
Cancer Treatment Reviews, 2022, 111 pp. 102480 -
ELSEVIER SCI LTD